Acrobiosystems Co

Acrobiosystems Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 1.13. In the previous year, Financial Leverage (Equity Multiplier) was 1.11 — a change of 1.63% (higher).

Financial Leverage

1.13

YoY

1.63%

Last updated:

Financial Leverage (Equity Multiplier) of Acrobiosystems Co is 2025 1.13 . Financial Leverage (Equity Multiplier) of Acrobiosystems Co was 2024 1.11 . It decreases by 1.63% higher compared to the previous year.

The Acrobiosystems Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.14 CNY
Jan 1, 2019
1.17 CNY
Jan 1, 2020
1.20 CNY
Jan 1, 2021
1.03 CNY
Jan 1, 2022
1.07 CNY
Jan 1, 2023
1.09 CNY
Jan 1, 2024
1.11 CNY
Jan 1, 2025
1.13 CNY
The Acrobiosystems Co Financial Leverage history
YEARFinancial LeverageYoY
1.13+1.63%
1.11+2.56%
1.09+1.79%
1.07+3.48%
1.03-14.39%
1.20+3.42%
1.17+2.32%
1.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Financial Leverage (Equity Multiplier) of Acrobiosystems Co is 1.13 in 2025.

Financial Leverage (Equity Multiplier) of Acrobiosystems Co changed from 1.11 to 1.13, representing a 1.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co